New stock news | "H. pylori nemesis" DNS Pharmaceutical (06872) attracts hot listings.

Danuo Pharmaceuticals (06872), known as the "Helicobacter pylori killer", will be listed from May 14 to May 19, 2026. According to the prospectus, the company is a biotechnology company approaching the commercialization stage, focusing on the discovery, development, and commercialization of differentiated innovative drug products to address unmet clinical needs in the field of bacterial infections and bacterial metabolism-related diseases. As of May 4, 2026, the company has established a pipeline consisting of seven innovative projects, including two core products: Lifotetsinazole (TNP-2198), a new molecular entity (NME) candidate drug, used as part of triple therapy with amoxicillin and proton pump inhibitors (PPIs) for the treatment of Helicobacter pylori infection and as a monotherapy for bacterial vaginosis and difficile infection; and Lifuquinoxetine (TNP-2092 injection), a triple-target candidate drug for implant-related bacterial infections (such as prosthetic joint infections (PJI), left ventricular assist device infections (LVADI), and central venous catheter-related bloodstream infections (CRBSI)). The company continues to invest resources in research and development to lay a foundation for long-term development. In 2023, 2024, and 2025, the R&D expenses attributable to the company's core products were RMB 99.70 million, RMB 64.20 million, and RMB 60.50 million respectively, accounting for 91.9%, 91.9%, and 84.1% of the total R&D expenses of the company, as well as 78.0%, 77.4%, and 50.1% of the company's total operating expenses (i.e. R&D expenses and administrative expenses) for the respective years/periods.